Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis.

HomeCirculationVol. 141, No. 24Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBMajor Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis Lili Zhang, MD, ScM, Daniel A. Zlotoff, MD, PhD, Magid Awadalla, MD, Syed S. Mahmood, MD, MPH, Anju Nohria, MD, Malek Z.O. Hassan, MD, Franck Thuny, MD, PhD, Leyre Zubiri, MD, PhD, Carol L. Chen, MD, Ryan J. Sullivan, MD, Raza M. Alvi, MD, Adam Rokicki, BS, Sean P. Murphy, MB, BCh, BAO, Maeve Jones-O’Connor, MD, Lucie M. Heinzerling, MD, MPH, Ana Barac, MD, PhD, Brian J. Forrestal, MD, Eric H. Yang, MD, Dipti Gupta, MD, MPH, Michael C. Kirchberger, MD, Sachin P. Shah, MD, Muhammad A. Rizvi, MD, Gagan Sahni, MD, Anant Mandawat, MD, Michael Mahmoudi, MD, PhD, Sarju Ganatra, MD, Stephane Ederhy, MD, Eduardo Zatarain-Nicolas, MD, PhD, John D. Groarke, MB, BCh, MPH, Carlo G. Tocchetti, MD, PhD, Alexander R. Lyon, MD, PhD, Paaladinesh Thavendiranathan, MD, Justine V. Cohen, DO, Kerry L. Reynolds, MD, Michael G. Fradley, MD and Tomas G. Neilan, MD, MPH Lili ZhangLili Zhang Tomas G. Neilan, MD, MPH, Cardio-Oncology Program, Cardiovascular Imaging Research Center, Massachusetts General Hospital, 165 Cambridge St, Suite 400, Boston, MA 02114. Email E-mail Address: [email protected] Cardiovascular Imaging Research Center, Division of Cardiology and Department of Radiology (L. Zhang, M.A., M.Z.O.H., R.M.A., A.R., T.G.N.), Massachusetts General Hospital, Boston. Cardio-Oncology Program, Division of Cardiology, Department of Medicine (L. Zhang, D.A.Z., M.A., S.P.M., M.J.-O., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author , Daniel A. ZlotoffDaniel A. Zlotoff Cardio-Oncology Program, Division of Cardiology, Department of Medicine (L. Zhang, D.A.Z., M.A., S.P.M., M.J.-O., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author , Magid AwadallaMagid Awadalla Cardiovascular Imaging Research Center, Division of Cardiology and Department of Radiology (L. Zhang, M.A., M.Z.O.H., R.M.A., A.R., T.G.N.), Massachusetts General Hospital, Boston. Cardio-Oncology Program, Division of Cardiology, Department of Medicine (L. Zhang, D.A.Z., M.A., S.P.M., M.J.-O., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author , Syed S. MahmoodSyed S. Mahmood Cardiology Division, New York-Presbyterian Hospital, Weill Cornell Medical Center (S.S.M.). Search for more papers by this author , Anju NohriaAnju Nohria Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA (A.N., J.D.G.). Search for more papers by this author , Malek Z.O. HassanMalek Z.O. Hassan Cardiovascular Imaging Research Center, Division of Cardiology and Department of Radiology (L. Zhang, M.A., M.Z.O.H., R.M.A., A.R., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author , Franck ThunyFranck Thuny Aix-Marseille University, Assistance Publique – Hôpitaux de Marseille, University Mediterranean Center of Cardio-Oncology, Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Center for Cardiovascular and Nutrition Research, France (F.T.). Mediterranean Group of Cardio-Oncology, Marseille, France (F.T.). Search for more papers by this author , Leyre ZubiriLeyre Zubiri Division of Oncology and Hematology, Department of Medicine (L. Zubiri, R.J.S., J.V.C., K.L.R.), Massachusetts General Hospital, Boston. Search for more papers by this author , Carol L. ChenCarol L. Chen Cardiology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York (C.LC., D.G.). Search for more papers by this author , Ryan J. SullivanRyan J. Sullivan Division of Oncology and Hematology, Department of Medicine (L. Zubiri, R.J.S., J.V.C., K.L.R.), Massachusetts General Hospital, Boston. Search for more papers by this author , Raza M. AlviRaza M. Alvi Cardiovascular Imaging Research Center, Division of Cardiology and Department of Radiology (L. Zhang, M.A., M.Z.O.H., R.M.A., A.R., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author , Adam RokickiAdam Rokicki Cardiovascular Imaging Research Center, Division of Cardiology and Department of Radiology (L. Zhang, M.A., M.Z.O.H., R.M.A., A.R., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author , Sean P. MurphySean P. Murphy Cardio-Oncology Program, Division of Cardiology, Department of Medicine (L. Zhang, D.A.Z., M.A., S.P.M., M.J.-O., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author , Maeve Jones-O’ConnorMaeve Jones-O’Connor Cardio-Oncology Program, Division of Cardiology, Department of Medicine (L. Zhang, D.A.Z., M.A., S.P.M., M.J.-O., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author , Lucie M. HeinzerlingLucie M. Heinzerling Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Germany (L.M.H., M.C.K.). Search for more papers by this author , Ana BaracAna Barac Cardio-Oncology Program, MedStar Heart and Vascular Institute, Georgetown University, Washington, DC (A.B., B.J.F.). Search for more papers by this author , Brian J. ForrestalBrian J. Forrestal Cardio-Oncology Program, MedStar Heart and Vascular Institute, Georgetown University, Washington, DC (A.B., B.J.F.). Search for more papers by this author , Eric H. YangEric H. Yang UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles (E.H.Y.). Search for more papers by this author , Dipti GuptaDipti Gupta Cardiology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York (C.LC., D.G.). Search for more papers by this author , Michael C. KirchbergerMichael C. Kirchberger Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Germany (L.M.H., M.C.K.). Search for more papers by this author , Sachin P. ShahSachin P. Shah Cardiology Division, Lahey Hospital and Medical Center, Burlington, MA (S.P.S., S.G.). Search for more papers by this author , Muhammad A. RizviMuhammad A. Rizvi Division of Oncology and Hematology, Department of Medicine, Lehigh Valley Hospital, Allentown, PA (M.A.R.). Search for more papers by this author , Gagan SahniGagan Sahni Mount Sinai Hospital, New York (G.S.). Search for more papers by this author , Anant MandawatAnant Mandawat Cardio-Oncology Program, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA (A.M.). Search for more papers by this author , Michael MahmoudiMichael Mahmoudi Faculty of Medicine, University of Southampton, United Kingdom (M.M.). Search for more papers by this author , Sarju GanatraSarju Ganatra Cardiology Division, Lahey Hospital and Medical Center, Burlington, MA (S.P.S., S.G.). Search for more papers by this author , Stephane EderhyStephane Ederhy AP-HP, Saint-Antoine Hospital, Department of Cardiology, UNICO-GRECO Cardio-Oncology Program, Paris, France (S.E.). Search for more papers by this author , Eduardo Zatarain-NicolasEduardo Zatarain-Nicolas Service of Cardiology, General University Hospital Gregorio Marañón, Madrid, Spain (E.Z.-N.). Search for more papers by this author , John D. GroarkeJohn D. Groarke Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA (A.N., J.D.G.). Search for more papers by this author , Carlo G. TocchettiCarlo G. Tocchetti Department of Translational Medical Sciences, Federico II University, Naples, Italy (C.G.T.). Search for more papers by this author , Alexander R. LyonAlexander R. Lyon Cardio-Oncology Program, Royal Brompton Hospital, and Imperial College London, United Kingdom (A.R.L.). Search for more papers by this author , Paaladinesh ThavendiranathanPaaladinesh Thavendiranathan Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Division of Cardiology, Toronto General Hospital, University of Toronto, Ontario, Canada (P.T.). Search for more papers by this author , Justine V. CohenJustine V. Cohen Division of Oncology and Hematology, Department of Medicine (L. Zubiri, R.J.S., J.V.C., K.L.R.), Massachusetts General Hospital, Boston. Search for more papers by this author , Kerry L. ReynoldsKerry L. Reynolds Division of Oncology and Hematology, Department of Medicine (L. Zubiri, R.J.S., J.V.C., K.L.R.), Massachusetts General Hospital, Boston. Search for more papers by this author , Michael G. FradleyMichael G. Fradley Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania, Philadelphia (M.G.F.). Search for more papers by this author and Tomas G. NeilanTomas G. Neilan Cardiovascular Imaging Research Center, Division of Cardiology and Department of Radiology (L. Zhang, M.A., M.Z.O.H., R.M.A., A.R., T.G.N.), Massachusetts General Hospital, Boston. Cardio-Oncology Program, Division of Cardiology, Department of Medicine (L. Zhang, D.A.Z., M.A., S.P.M., M.J.-O., T.G.N.), Massachusetts General Hospital, Boston. Search for more papers by this author Originally published15 Jun 2020https://doi.org/10.1161/CIRCULATIONAHA.119.044703Circulation. 2020;141:2031–2034Immune checkpoint inhibitors (ICIs) are being increasingly applied to a broader range of cancers. Myocarditis is an uncommon but potentially fulminant toxicity associated with ICIs, with a case fatality rate of 30% to 50%.1,2 Corticosteroids are the first-line treatment; however, because of the limited data, guidelines vary significantly in terms of initial corticosteroid dose and treatment strategies.3,4An international multicenter registry of ICI-associated myocarditis from 23 sites was established by retrospectively collecting consecutive patients with ICI-associated myocarditis. The diagnosis was made in 1 of 2 ways: (1) histopathology or (2) clinically suspected myocarditis based on the European Society of Cardiology guidelines.5 The study was approved by each center’s institutional review board. The dose of corticosteroids was converted to methylprednisolone equivalents. Patients were categorized into low-dose (<60 mg/d), intermediate-dose (60–500 mg/d), and high-dose (501–1000 mg/d) groups based on initial methylprednisolone equivalent administered on the first day of treatment. The time of initiation was the time from admission to the first dose of corticosteroids, separated into groups of ≤24 hours, 24 to 72 hours, and >72 hours. Major adverse cardiac events (MACE) were a composite of cardiovascular death, cardiac arrest, cardiogenic shock, and hemodynamically significant complete heart block requiring pacemaker. The beginning of follow-up was the time of index admission for myocarditis, and the end of follow-up was May 1, 2019.In total, 126 patients were treated with corticosteroids, with 65 diagnosed by histopathology and 61 with clinical criteria. Sixteen of the 126 patients used additional immunosuppressant drugs, with similar characteristics as patients who received corticosteroids only. The median time from ICI administration to the admission was 51 days (interquartile range, 23–120 days). Eighty-four patients (67%) presented with signs or symptoms typical for heart failure, and 39 (31%) presented with arrhythmia. The initial corticosteroid was either methylprednisolone (96 [76%]), prednisone (25 [20%]), hydrocortisone (2 [2%]), or dexamethasone (3 [2%]). Twenty-one patients (16.7%) received low-dose corticosteroids, 55 (43.7%) received intermediate-dose corticosteroids, and 50 (39.6%) received high-dose corticosteroids; groups were broadly similar in characteristics. Patients who received corticosteroids within 24 hours (43 [34.1%]), between 24 and 72 hours (35 [27.8%]), and after 72 hours (43 [38.1%]) also appeared similar in characteristics. Patients who received corticosteroids within 24 hours were less likely to have persistent troponin elevation at discharge (reduction of <50% of the peak troponin levels; 32.4%) than those treated between 24 and 72 hours (66.7%) and after 72 hours (41.4%; P=0.026). There was an inverse relationship between initial dose of corticosteroids and the occurrence of MACE (low dose, 61.9%; intermediate dose, 54.6%; high dose, 22.0%; P<0.001; Figure [A]). Compared with low-dose corticosteroids, high dose was associated with a 73% lower risk of MACE independent of age, sex, lowest left ventricular ejection fraction, and time of initiation (hazard ratio, 0.27 [95% CI, 0.09–0.84]; P=0.024). Patients receiving corticosteroids within 24 hours of admission also had a lower rate of MACE (7.0%) than those receiving corticosteroids between 24 and 72 hours (34.3%) and those receiving corticosteroids at >72 hours (85.1%; P<0.001; Figure [B]). Compared with after 72 hours, initiation of corticosteroids within 24 hours of admission (hazard ratio, 0.03 [95% CI, 0.004–0.23]; P=0.001) and between 24 and 72 hours (hazard ratio, 0.30 [95% CI, 0.12–0.73]; P=0.008) was associated with a lower risk of MACE after adjustment for age, sex, lowest left ventricular ejection fraction, and initial corticosteroid dose. Patients were further categorized into time and dose combination groups, by dividing the cohort into ≤24 hours, 24 to 72 hours, and >72 hours and high-dose (methylprednisolone 1000 mg/d) and non–high-dose corticosteroids (any dose <1000 mg/d) groups. The time of initiation impacted MACE-free survival, whereby patients receiving corticosteroids within 24 hours, regardless of dosage (blue curves), showed the best outcome, and patients receiving corticosteroids after 72 hours, regardless of dosage (red curves), showed the worst outcome (Figure [C]).Download figureDownload PowerPointFigure. Relationship between initial corticosteroids dose and timing and MACE-free survival. Kaplan-Meier curves by initial corticosteroids dose (A), by time of initiation (B), and by initial dose of corticosteroids and time of initiation combination (C). MACE indicates major adverse cardiovascular events.These results raise the possibility that myocardial damage can be mitigated by early and intensive corticosteroid therapy.3,4 There appeared to be a graded reduction in the risk of MACE as the time of initiation became shorter and initial dose became higher. The initiation time of corticosteroids appeared to play a stronger role, such that using high-dose corticosteroids could not overcome the effect of corticosteroids given later. In contrast, non–high-dose corticosteroids administered within 24 hours may lead to a better outcome as compared to patients who receive high-dose corticosteroids later (24–72 or >72 hours).This was a retrospective observational study; therefore, the association of corticosteroid dosing and time is hypothesis generating, and future randomized, controlled trials will be needed to provide more definitive evidence and closely monitor cancer outcomes. Specifically, the effect of high-dose corticosteroids on cancer outcomes with ICIs is unclear; initial data suggested that cancer outcomes were unchanged by high-dose corticosteroids, but more recent data suggest that cancer survival may be reduced. Therefore, there is likely a pressing need for therapies beyond corticosteroids that will not affect cancer outcomes.In conclusion, higher initial dose (ie, intravenous methylprednisolone 1000 mg/d) and earlier initiation of corticosteroids in a retrospective study were associated with improved cardiac outcomes with ICI-associated myocarditis.Sources of FundingThis work was supported by the Sarnoff Cardiovascular Research Foundation and the New York Academy of Medicine’s Glorney-Raisbeck Award to Dr Mahmood. Dr Sullivan was supported in part through the National Institutes of Health (NIH)/National Cancer Institute (NCI) (RO1CA229851, UH2CA207355, RO1CA193970). Drs Chen and Gupta were supported in part through the NIH/NCI (P30CA008748). Dr Thavendiranathan was supported in part through the Canadian Institutes of Health Research New Investigator Award (FRN 147814). Dr Tocchetti was supported by a Ricerca di Ateneo/Federico II University grant. Dr Neilan was supported in part through a kind gift from A. Curt Greer and Pamela Kohlberg, NIH/National Heart, Lung, and Blood Institute (1RO1HL130539, 1RO1HL137562, and K24HL150238), and NIH/Harvard Center for AIDS Research (P30 AI060354).DisclosuresDr Mahmood has received consultancy fees from OMR Globus, Alpha Detail, and Opinion Research Team. Dr Nohria has received research support from Amgen and has been a consultant for Takeda Oncology. Dr Heinzerling has received consultancy, advisory board, and speaker fees from MSD, BMS, Roche, Novartis, Amgen, Curevac, Sanofi and Pierre Fabre. Dr Sullivan has been a consultant to Merck and Novartis. Dr Groarke has received research support from Amgen. Dr Neilan has received advisory fees from Parexel, BMS, H3-Biomedicine, Syros Pharmaceuticals, Aprea Therapeutics, and Intrinsic Imaging. The other authors report no conflicts.FootnotesThe full author list is available on page 2033.https://www.ahajournals.org/journal/circTomas G. Neilan, MD, MPH, Cardio-Oncology Program, Cardiovascular Imaging Research Center, Massachusetts General Hospital, 165 Cambridge St, Suite 400, Boston, MA 02114. Email [email protected]harvard.eduReferences1. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, et al. Myocarditis in patients treated with immune checkpoint inhibitors.J Am Coll Cardiol. 2018; 71:1755–1764. doi: 10.1016/j.jacc.2018.02.037CrossrefMedlineGoogle Scholar2. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, Murphy SP, Mercaldo ND, Zhang L, Zlotoff DA, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis.J Am Coll Cardiol. 2020; 75:467–478. doi: 10.1016/j.jacc.2019.11.049CrossrefMedlineGoogle Scholar3. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.J Clin Oncol. 2018; 36:1714–1768. doi: 10.1200/JCO.2017.77.6385CrossrefMedlineGoogle Scholar4. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al; Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.J Immunother Cancer. 2017; 5:95. doi: 10.1186/s40425-017-0300-zCrossrefMedlineGoogle Scholar5. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, et al; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.Eur Heart J. 2013; 34:2636–48, 2648a. doi: 10.1093/eurheartj/eht210CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByShen H, Lian Y, Yin J, Zhu M, Yang C, Tu C, Peng Y, Li X and Zhang J (2023) Cardiovascular Risk Stratification by Automatic Coronary Artery Calcium Scoring on Pretreatment Chest Computed Tomography in Diffuse Large B-Cell Lymphoma Receiving Anthracycline-Based Chemotherapy: A Multicenter Study, Circulation: Cardiovascular Imaging, 16:2, (e014829), Online publication date: 1-Feb-2023. Naimi A, Mohammed R, Raji A, Chupradit S, Yumashev A, Suksatan W, Shalaby M, Thangavelu L, Kamrava S, Shomali N, Sohrabi A, Adili A, Noroozi-Aghideh A and Razeghian E (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons, Cell Communication and Signaling, 10.1186/s12964-022-00854-y, 20:1, Online publication date: 1-Dec-2022. Vafaei S, Zekiy A, Khanamir R, Zaman B, Ghayourvahdat A, Azimizonuzi H and Zamani M (2022) Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier, Cancer Cell International, 10.1186/s12935-021-02407-8, 22:1, Online publication date: 1-Dec-2022. Huang W, Xu R, Zhou B, Lin C, Guo Y, Xu H and Guo X (2022) Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.912329, 9 Faubry C, Faure M, Toublanc A, Veillon R, Lemaître A, Vergnenègre C, Cochet H, Khan S, Raherison C, Dos Santos P and Zysman M (2022) A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.878211, 9 Anstadt E, Chu B, Yegya-Raman N, Han X, Doucette A, Poirier K, Mohiuddin J, Maity A, Facciabene A, Amaravadi R, Karakousis G, Cohen J, Mitchell T, Schuchter L and Lukens J (2022) Moderate Colitis Not Requiring IV Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy, The Oncologist, 10.1093/oncolo/oyac108 Naqash A, Moey M, Cherie Tan X, Laharwal M, Hill V, Moka N, Finnigan S, Murray J, Johnson D, Moslehi J and Sharon E (2022) Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program, Journal of Clinical Oncology, 10.1200/JCO.22.00369 Cadour F, Cautela J, Rapacchi S, Varoquaux A, Habert P, Arnaud F, Jacquier A, Meilhac A, Paganelli F, Lalevée N, Scemama U and Thuny F (2022) Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor–induced Myocarditis, Radiology, 10.1148/radiol.211765, 303:3, (512-521), Online publication date: 1-Jun-2022. Kaakoua M, Djenaoui S, Joseph N, Mohamed A, Zanardo L, Samy E, Poenou G, Chidiac J and Mahe I (2022) Myocardite immuno-médiée : toxicité rare, grave et létale des inhibiteurs de points de contrôle immunitaire, La Revue de Médecine Interne, 10.1016/j.revmed.2022.03.162, 43, (A216), Online publication date: 1-Jun-2022. Xu Y, Hong L and Liu T (2022) Ominous Electrocardiographic Abnormalities in a Patient With Hepatocellular Carcinoma, JAMA Internal Medicine, 10.1001/jamainternmed.2022.1226, 182:6, (674), Online publication date: 1-Jun-2022. Nakagomi Y, Tajiri K, Shimada S, Li S, Inoue K, Murakata Y, Murata M, Sakai S, Sato K and Ieda M (2022) Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature, Frontiers in Pharmacology, 10.3389/fphar.2022.884776, 13 Power J, Keyt L and Adler E (2022) Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2022.2066522, 20:4, (241-251), Online publication date: 3-Apr-2022. Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti C and Varricchi G (2022) Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events, Frontiers in Immunology, 10.3389/fimmu.2022.804597, 13 Ammirati E, Bizzi E, Veronese G, Groh M, Van de Heyning C, Lehtonen J, Pineton de Chambrun M, Cereda A, Picchi C, Trotta L, Moslehi J and Brucato A (2022) Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis, Frontiers in Medicine, 10.3389/fmed.2022.838564, 9 Briasoulis A, Chasouraki A, Sianis A, Panagiotou N, Kourek C, Ntalianis A and Paraskevaidis I (2022) Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents, Journal of Cardiovascular Development and Disease, 10.3390/jcdd9030066, 9:3, (66) Gilon D, Iakobishvili Z and Leibowitz D (2022) The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond, Vaccines, 10.3390/vaccines10020304, 10:2, (304) Ederhy S, Devos P, Pinna B, Funck-Brentano E, Abbar B, Fenioux C, Cohen A, Moslehi J, Bretagne M, Allenbach Y, Kharroubi D and Salem J (2022) 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis, Archives of Cardiovascular Diseases, 10.1016/j.acvd.2021.12.001, 115:2, (114-116), Online publication date: 1-Feb-2022. Mukunda N, Vallabhaneni S, Lefebvre B and Fradley M (2022) Cardiotoxicity of Systemic Melanoma Treatments, Current Treatment Options in Oncology, 10.1007/s11864-021-00924-2, 23:2, (240-253), Online publication date: 1-Feb-2022. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon A, López-Fernández T, Fradley M, Ganatra S, Curigliano G, Mitchell J, Minotti G, Lang N, Liu J, Neilan T, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds K, Ruddy K, Thavendiranathan P and Valent P (2021) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement, European Heart Journal, 10.1093/eurheartj/ehab674, 43:4, (280-299), Online publication date: 31-Jan-2022. Naganuma K, Horita Y, Matsuo K, Miyama Y, Mihara Y, Yasuda M, Nakano S and Hamaguchi T (2022) An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer, Internal Medicine, 10.2169/internalmedicine.9161-21, . Nishikawa T, Kunimasa K, Ohta-Ogo K, Ikeda Y, Yasui T, Shioyama W, Oka T, Honma K, Hatakeyama K, Kumagai T and Fujita M (2022) Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis: A Case Report, Internal Medicine, 10.2169/internalmedicine.8575-21, . Jain A, Bruno K, Matsumori A, Cooper L, Yamani M and Fairweather D (2022) Myocarditis and Pericarditis Comprehensive Pharmacology, 10.1016/B978-0-12-820472-6.00091-8, (413-431), . Kondapalli L and Neilan T (2021) Immune checkpoint inhibitors and cardiovascular events among patients with cancer: a window into the critical role of the immune system in cardiovascular biology, European Heart Journal, 10.1093/eurheartj/ehab708, 42:48, (4978-4980), Online publication date: 21-Dec-2021. Wang C, Lin J, Wang Y, Hsi D, Chen J, Liu T, Zhou Y, Ren Z, Zeng Z, Cheng L and Ge J (2021) Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment, Frontiers in Pharmacology, 10.3389/fphar.2021.770631, 12 Waheed N, Fradley M, DeRemer D, Mahmoud A, Shah C, Langaee T, Lipori G, March K, Pepine C, Cooper-DeHoff R, Wu Y and Gong Y (2021) Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center, Cardio-Oncology, 10.1186/s40959-021-00097-9, 7:1, Online publication date: 1-Dec-2021. Zhang R, Padegimas A, Murphy K, Evans P, Peters C, Domenico C, Vidula M, Mather P, Cevasco M, Cohen R, Carver J and O’Quinn R (2021) Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series, Cardio-Oncology, 10.1186/s40959-021-00095-x, 7:1, Online publication date: 1-Dec-2021. Castillo R, Sandefur B, Finch A, Richter M and Thanarajasingam U (2021) Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department, Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 10.1016/j.mayocpiqo.2021.09.007, 5:6, (1029-1035), Online publication date: 1-Dec-2021. Lopez-Mattei J, Yang E, Ferencik M, Baldassarre L, Dent S and Budoff M (2021) Cardiac Computed Tomography in Cardio-Oncology, JACC: CardioOncology, 10.1016/j.jaccao.2021.09.010, 3:5, (635-649), Online publication date: 1-Dec-2021. Stein-Merlob A, Rothberg M, Ribas A and Yang E (2021) Cardiotoxicities of novel cancer immunotherapies, Heart, 10.1136/heartjnl-2020-318083, 107:21, (1694-1703), Online publication date: 1-Nov-2021. Gong J, Drobni Z, Alvi R, Murphy S, Sullivan R, Hartmann S, Gilman H, Lee H, Zubiri L, Raghu V, Karp-Leaf R, Zafar A, Zlotoff D, Frigault M, Reynolds K and Neilan T (2021) Immune checkpoint inhibitors for cancer and venous thromboembolic events, European Journal of Cancer, 10.1016/j.ejca.2021.09.010, 158, (99-110), Online publication date: 1-Nov-2021. Liu Q, Yu Y, Lin J, Wang Y, Ai L, Li Q, Wu W, Jin H, Li S, Liu M, Yu S and Liu T (2021) Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity, European Journal of Cancer, 10.1016/j.ejca.2021.07.023, 157, (10-20), Online publication date: 1-Nov-2021. Lehmann L, Cautela J, Palaskas N, Baik A, Meijers W, Allenbach Y, Alexandre J, Rassaf T, Müller O, Aras M, Asnani A, Deswal A, Laufer-Perl M, Thuny F, Kerneis M, Hayek S, Ederhy S, Salem J and Moslehi J (2021) Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis, JAMA Cardiology, 10.1001/jamacardio.2021.2241, 6:11, (1329), Online publication date: 1-Nov-2021. Hajjo R, Sabbah D, Bardaweel S and Tropsha A (